Education
About Us
Working with TipRanks
Follow Us
Pds Biotechnology (PDSB)
NASDAQ:PDSB
PDSB Stock Chart & Stats
$0.73
-$0.09(-5.36%)
At close: 4:00 PM EST
$0.73
-$0.09(-5.36%)
Day’s Range― - ―
52-Week Range$0.70 - $2.20
Previous CloseN/A
Volume197.50K
Average Volume (3M)745.10K
Market Cap
$39.95M
Enterprise Value$29.54M
Total Cash (Recent Filing)$26.20M
Total Debt (Recent Filing)$17.97M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Mar 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding54,721,306
10 Day Avg. Volume945,146
30 Day Avg. Volume745,097
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.95K
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$9.00Price Target Upside1132.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalPhase 2 results and SITC mechanistic data showing immune pathway activation provide a strong progression-free survival signal versus current standard treatment, reinforcing the rationale for the endpoint change.
Regulatory PathwayFDA alignment to allow progression-free survival as the basis for a potential accelerated approval gives PDS0101 a nearer-term regulatory milestone that could enable earlier market entry.
Trial Design And Cash BurnProtocol amendment to designate progression-free survival as the primary endpoint and reduce enrollment aims to shorten trial duration and lower operational costs, supporting reduced cash burn.
Bears Say
Accelerated Approval RiskAn accelerated approval based on progression-free survival would still require confirmatory overall survival evidence, creating the risk of additional trials or regulatory restrictions if long-term benefit is not confirmed.
Overall Survival RequirementFull traditional approval still depends on demonstrating improved overall survival, so final approval will require longer-term survival data and may delay permanent market authorization.
Reimbursement And AdoptionPayers and clinicians may be reluctant to broadly adopt or reimburse a therapy approved on progression-free survival alone without mature overall survival data, limiting early commercial uptake.
PDS Biotechnology News
PDSB FAQ
What was Pds Biotechnology’s price range in the past 12 months?
Pds Biotechnology lowest stock price was $0.70 and its highest was $2.20 in the past 12 months.
What is Pds Biotechnology’s market cap?
Pds Biotechnology’s market cap is $39.95M.
When is Pds Biotechnology’s upcoming earnings report date?
Pds Biotechnology’s upcoming earnings report date is Mar 26, 2026 which is in 47 days.
How were Pds Biotechnology’s earnings last quarter?
Pds Biotechnology released its earnings results on Nov 13, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.197 by $0.007.
Is Pds Biotechnology overvalued?
According to Wall Street analysts Pds Biotechnology’s price is currently Undervalued.
Does Pds Biotechnology pay dividends?
Pds Biotechnology does not currently pay dividends.
What is Pds Biotechnology’s EPS estimate?
Pds Biotechnology’s EPS estimate is -0.2.
How many shares outstanding does Pds Biotechnology have?
Pds Biotechnology has 54,721,306 shares outstanding.
What happened to Pds Biotechnology’s price movement after its last earnings report?
Pds Biotechnology reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.197. Following the earnings report the stock price went down -12.253%.
Which hedge fund is a major shareholder of Pds Biotechnology?
Currently, no hedge funds are holding shares in PDSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (1132.88% Upside)
$9.00 (1132.88% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.37%
12-Months-Change
Fundamentals
Return on Equity
-221.81%
Trailing 12-Months
Asset Growth
-33.83%
Trailing 12-Months
Company Description
Pds Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
PDSB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with significant achievements in clinical trial progress and strategic amendments to enhance regulatory approval processes. However, financial challenges and a temporary trial pause highlight ongoing operational and funding hurdles.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$9.00
▲(1132.88% Upside)
Technical Analysis
Ownership Overview
1.54% Insiders
3.82% Mutual Funds
0.35% Other Institutional Investors
91.19% Public Companies and
Individual Investors